Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial

Diabetes, Obesity and Metabolism

Volumn 19, Issue 3, 2017, Pages 442-447

  Yabe, Daisuke ^a,b,c   Eto, Takashi ^d   Shiramoto, Masanari ^d   Irie, Shin ^d   Murotani, Kenta ^e   Seino, Yusuke ^f   Kuwata, Hitoshi ^a,b   Kurose, Takeshi ^a,b   Seino, Susumu ^c   Ahrén, Bo ^g   Seino, Yutaka ^a,b  

^a Kobe Biotechnology Research and Human Resource Development Center   (Japan)

^b KANSAI ELECTRIC POWER CO   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Hakata Clinic   (Japan)

^e AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^f NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g LUND UNIVERSITY   (Sweden)

Author keywords

DPP 4 inhibitor; GLP 1 receptor agonist; glucagon response; hypoglycaemia; sympatho adrenal response

Indexed keywords

EPINEPHRINE; GLUCAGON; GROWTH HORMONE; HYDROCORTISONE; LINAGLIPTIN; LIRAGLUTIDE; NORADRENALIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HUMAN GROWTH HORMONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE TOLERANCE TEST; HORMONE RESPONSE; HUMAN; HYPOGLYCEMIA; JAPANESE (PEOPLE); MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; AGED; AGONISTS; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; GLUCOSE CLAMP TECHNIQUE; JAPAN; METABOLISM; MIDDLE AGED;

AGED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; EPINEPHRINE; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE CLAMP TECHNIQUE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; JAPAN; LINAGLIPTIN; LIRAGLUTIDE; MALE; MIDDLE AGED; NOREPINEPHRINE;

EID: 85006240253     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12817     Document Type: Article

References (20)

1. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14:2047-2058.
2. Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Invest. 2016;7:102-109.
3. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: silimarities and differences. J Diabetes Invest. 2010;1:9-23.
4. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. 2013;62:3316-3323.
5. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87:1239-1246.
6. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91:301-307.
7. Christensen MB, Calanna S, Holst JJ, Vilsboll T, Knop FK. Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. J Clin Endocrinol Metab. 2014;99:E418-E426.
8. Taminato T, Seino Y, Goto Y, Inoue Y, Kadowaki S. Synthetic gastric inhibitory polypeptide. Stimulatory effect on insulin and glucagon secretion in the rat. Diabetes. 1977;26:480-484.
9. Christensen M, Vedtofte L, Holst JJ, Vilsboll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011;60:3103-3109.
10. Malmgren S, Ahren B. DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice. Diabetologia. 2015;58:1091-1099.
11. Ahren B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:1236-1243.
12. Hompesch M, Jones-Leone A, Carr MC, et al. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:82-90.
13. Farngren J, Persson M, Ahren B. Effect of the GLP-1 receptor agonist lixisenatide on counterregulatory responses to hypoglycemia in subjects with insulin-treated type 2 diabetes. Diabetes Care. 2016;39:242-249.
14. Farngren J, Persson M, Schweizer A, Foley JE, Ahren B. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. Diabetes Obes Metab. 2014;16:812-818.
15. Yabe D, Seino Y, Fukushima M, Seino S. Beta cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15:602.
16. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and Non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56:696-708.
17. Kim YG, Hahn S, Oh TJ, Park KS, Cho YM. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:900-909.
18. Aaboe K, Akram S, Deacon CF, Holst JJ, Madsbad S, Krarup T. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2015;7:74-81.
19. Farngren J, Persson M, Schweizer A, Foley JE, Ahren B. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab. 2012;97:3799-3806.
20. Pieber TR, Deller S, Korsatko S, et al. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial. Diabetes Obes Metab. 2015;17:742-750.